Clinical trial
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV…
NCT00430534 · Henogen, Industry · Completed
Key facts
| NCT number | NCT00430534 |
|---|---|
| Title | Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664). |
| Official title | To Evaluate the Safety, Immunogenicity and Efficacy of GSK Biologicals' EBV Vaccine (268664) in Healthy Seronegative Adolescents/Adults When Injected Intramuscularly According to a 0-1-5 Month Schedule in Belgium. |
| Lead sponsor | Henogen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epstein Barr Virus (EBV) Infection |
| Intervention type | Biological |
| Interventions | EBV vaccine (268664) |
| Enrollment | 200 |
| First posted | Feb 2, 2007 |
| Last update posted | Feb 2, 2007 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: